- #UNITED KINGDOM TO REGRESS IMPERIAL MEASURES TRIAL#
- #UNITED KINGDOM TO REGRESS IMPERIAL MEASURES LICENSE#
- #UNITED KINGDOM TO REGRESS IMPERIAL MEASURES PLUS#
The mean (±SE) changes in the scores from baseline to week 6 were −8.0☑.0 points in the psilocybin group and −6.0☑.0 in the escitalopram group, for a between-group difference of 2.0 points (95% confidence interval, −5.0 to 0.9) (P=0.17). The mean scores on the QIDS-SR-16 at baseline were 14.5 in the psilocybin group and 16.4 in the escitalopram group. ResultsĪ total of 59 patients were enrolled 30 were assigned to the psilocybin group and 29 to the escitalopram group. There were 16 secondary outcomes, including QIDS-SR-16 response (defined as a reduction in score of >50%) and QIDS-SR-16 remission (defined as a score of ≤5) at week 6. The primary outcome was the change from baseline in the score on the 16-item Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR-16 scores range from 0 to 27, with higher scores indicating greater depression) at week 6.
#UNITED KINGDOM TO REGRESS IMPERIAL MEASURES PLUS#
Patients were assigned in a 1:1 ratio to receive two separate doses of 25 mg of psilocybin 3 weeks apart plus 6 weeks of daily placebo (psilocybin group) or two separate doses of 1 mg of psilocybin 3 weeks apart plus 6 weeks of daily oral escitalopram (escitalopram group) all the patients received psychological support.
#UNITED KINGDOM TO REGRESS IMPERIAL MEASURES TRIAL#
In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor, over a 6-week period. Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. The most trusted, influential source of new medical knowledge and clinical best practices in the world.
#UNITED KINGDOM TO REGRESS IMPERIAL MEASURES LICENSE#
Information and tools for librarians about site license offerings. Valuable tools for building a rewarding career in health care. The authorized source of trusted medical research and education for the Chinese-language medical community. The most advanced way to teach, practice, and assess clinical reasoning skills. Information, resources, and support needed to approach rotations - and life as a resident. The most effective and engaging way for clinicians to learn, improve their practice, and prepare for board exams. NEW! Peer-reviewed journal featuring in-depth articles to accelerate the transformation of health care delivery.Ĭoncise summaries and expert physician commentary that busy clinicians need to enhance patient care. NEW! A digital journal for innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.
0 kommentar(er)
